article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

However, in patients with urea cycle disorders, genetic defects result in inadequate amounts of the enzymes needed to convert nitrogen into urea. The University of California Los Angeles are currently investigating the use of genetically altered hepatocyte-like cells generated from induced pluripotent stem cells. Future Possibilities.

RNA 245
article thumbnail

The ins and outs of the life sciences: top hires for October 2022 

pharmaphorum

This month, we highlight new appointments from Lumeris, Lineage Cell Therapeutics, 1910 Genetics, and ADC Therapeutics. . ” Patrick Genestin, 1910 Genetics . “I am excited to join 1910 Genetics at such a pivotal time for the company,” Genestin said. Ben Grabski, Lumeris.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan

The Pharma Data

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.

article thumbnail

Leading commercial dose (non-sterile) companies in contract marketing

Pharmaceutical Technology

The production of commercial dose non-sterile products such as tablets, capsules, ointments, creams, and powders is rising due to their growing global demand, attributed to increasing demand for anti-ageing products, hereditary factors, genetic mutations, exposure to harmful radiation, and rising geriatric population.

Marketing 100
article thumbnail

A new era in diagnostics: The growing demand for POC testing

Pharmaceutical Technology

While nucleic acid amplification tests - a type of viral diagnostic test for a virus or bacterium that detects genetic materials rather than antigens or antibodies - can provide a shorter turnaround time, they come with challenges, ranging from their complex nature to the intensity of labour required in their creation.

article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Inactive viruses often act as the viral vector, as they’re able to deliver genetic therapies efficiently.

Genome 105
article thumbnail

Pfizer vaults into sickle cell market as GBT deal confirmed

pharmaphorum

The GBT deal comes at a time when the market for SCD therapies is undergoing significant change, with multiple new drugs reaching the market after years of stagnation and progress also being made with genetic therapies from the likes of bluebird bio, Vertex Pharma/CRISPR Therapeutics and Precision Bio/Novartis.

Marketing 111